Vamil Divan Analyst PerformanceSenior Biopharmaceuticals Research Analyst at GuggenheimVamil Divan is a stock analyst at Guggenheim focused in the medical sector, covering 37 publicly traded companies. Over the past year, Vamil Divan has issued 44 stock ratings, including buy and hold recommendations. While full access to Vamil Divan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Vamil Divan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings253 Last 11 YearsBuy Recommendations58.61% 143 Buy RatingsCompanies Covered37 Unique Companies Ratings Distribution244RatingsDistribution of strong buy, buy, hold, and sell ratings by Vamil Divan.RatingPercentageCount Strong Buy0.4%1 ratings Buy58.2%142 ratings Hold35.7%87 ratings Sell5.7%14 ratingsOut of 244 total stock ratings issued by Vamil Divan at Guggenheim, the majority (58.2%) have been Buy recommendations, followed by 35.7% Hold, 5.7% Sell, and 0.4% Strong Buy.Best & Worst CallsBest Call0000.0%SVRAMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BHVNOct 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ75.7% of companies on NASDAQ28 companiesNYSE24.3% of companies on NYSE9 companiesVamil Divan, an analyst at Guggenheim, currently covers 37 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical35 companies94.6%Consumer Discretionary1 company2.7%Manufacturing1 company2.7%Vamil Divan of Guggenheim specializes in stock coverage within the Medical sector, with additional focus on Consumer Discretionary and Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE16 companies43.2%MED - DRUGS7 companies18.9%LARGE CAP PHARMA5 companies13.5%MED - GENERIC DRG2 companies5.4%MED PRODUCTS2 companies5.4%PHARMACEUTICAL PREPARATIONS2 companies5.4%GAMING1 company2.7%MED INSTRUMENTS1 company2.7%Miscellaneous1 company2.7% Vamil Divan's Ratings History at Guggenheim Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsABSIAbsci6/15/2026Boost Price Target$6.80$15.00Buy$0.0000.00% ROIJBIOJade Biosciences6/2/2026Reiterated Rating$18.59$47.00Buy$0.0000.00% ROIASMBAssembly Biosciences5/28/2026Reiterated Rating$27.12$43.00Buy$0.0000.00% ROIUNCYUnicycive Therapeutics5/13/2026Reiterated Rating$8.17$37.00Buy$0.0000.00% ROIDKNGDraftKings5/11/2026Lower Price Target$25.52$35.00Buy$0.0000.00% ROIJBIOJade Biosciences5/11/2026Boost Price Target$25.81$32.00Buy$0.0000.00% ROIINSMInsmed5/8/2026Lower Price Target$105.36$226.00Buy$0.0000.00% ROIAMGNAmgen5/4/2026Lower Price Target$329.82$340.00Neutral$0.0000.00% ROIABBVAbbVie5/1/2026Reiterated Rating$208.01$249.00Buy$0.0000.00% ROITVTXTravere Therapeutics4/24/2026Boost Price Target$40.82$56.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. TVTXTravere Therapeutics4/14/2026Boost Price Target$30.70$54.00Buy$0.0000.00% ROIABBVAbbVie4/10/2026Boost Price Target$212.54$249.00Buy$0.0000.00% ROIAMGNAmgen4/9/2026Boost Price Target$350.09$351.00Neutral$0.0000.00% ROIASMBAssembly Biosciences4/6/2026Boost Price Target$29.01$43.00Buy$0.0000.00% ROIUNCYUnicycive Therapeutics4/2/2026Lower Price Target$6.94$40.00Buy$0.0000.00% ROIPFEPfizer3/24/2026Boost Price Target$26.77$36.00Buy$0.0000.00% ROIABBVAbbVie3/12/2026Reiterated Rating$227.58Buy$0.0000.00% ROIJBIOJade Biosciences3/11/2026Boost Price Target$14.48$23.00Buy$0.0000.00% ROIAMGNAmgen2/6/2026Boost Price Target$374.78$347.00Neutral$0.0000.00% ROIMRKMerck & Co., Inc.2/6/2026Boost Price Target$121.59$140.00Buy$0.0000.00% ROIJNJJohnson & Johnson1/23/2026Boost Price Target$218.58$240.00Buy$0.0000.00% ROIANIPANI Pharmaceuticals1/16/2026Boost Price Target$85.29$124.00Buy$0.0000.00% ROITVTXTravere Therapeutics1/14/2026Reiterated Rating$29.11$49.00Buy$0.0000.00% ROISVRASavara12/23/2025Reiterated Rating$6.47Buy$0.0000.00% ROIINSMInsmed12/18/2025Lower Price Target$198.46$221.00Buy$0.0000.00% ROIPFEPfizer12/17/2025Reiterated Rating$25.56Buy$0.0000.00% ROIJNJJohnson & Johnson12/5/2025Boost Price Target$202.24$227.00Buy$0.0000.00% ROIEOLSEvolus12/1/2025Lower Price Target$6.82$19.00Outperform$0.0000.00% ROIPFEPfizer11/24/2025Boost Price Target$25.02$35.00Buy$0.0000.00% ROIJBIOJade Biosciences11/18/2025Boost Price Target$12.59$17.00Buy$0.0000.00% ROIELDNEledon Pharmaceuticals11/18/2025Lower Price Target$1.62$8.00Buy$0.0000.00% ROIANIPANI Pharmaceuticals11/10/2025Boost Price Target$86.64$115.00Buy$0.0000.00% ROISCYXSCYNEXIS10/28/2025Lower Price Target$6.02$24.00Buy$0.0000.00% ROIABBVAbbVie10/20/2025Boost Price Target$229.66$242.00Buy$0.0000.00% ROIABBVAbbVie10/20/2025Boost Price Target$229.66$242.00Buy$0.0000.00% ROIJNJJohnson & Johnson9/23/2025Upgrade$174.22$206.00Buy$0.0000.00% ROISVRASavara9/9/2025Boost Price Target$3.85$11.00Buy$0.0000.00% ROIVALNValneva9/8/2025Lower Price Target$8.34$13.00Buy$0.0000.00% ROIANIPANI Pharmaceuticals9/8/2025Boost Price Target$95.91$114.00Buy$0.0000.00% ROIINSMInsmed9/8/2025Boost Price Target$145.83$172.00Buy$0.0000.00% ROIThe U.S. Government Just Turned Tax Dollars1 into 407% Gains (Ad)The U.S. Government has quietly built a stock portfolio that's up 278% in less than nine months - 26 times better than the S&P 500. The track record includes MP Materials up 229%, Intel up 131%, Lithium Americas up 227%, and Trilogy Metals up 407%. Weiss Ratings strategist Michael Robinson believes he's identified the next company on Uncle Sam's buy list.See the company Michael Robinson believes the government buys nextASMBAssembly Biosciences9/8/2025Boost Price Target$23.80$39.00Buy$0.0000.00% ROIABBVAbbVie8/1/2025Boost Price Target$193.55$227.00Buy$0.0000.00% ROIJNJJohnson & Johnson7/17/2025Reiterated Rating$163.41$167.00Neutral$0.0000.00% ROIPROKProKidney7/14/2025Reiterated Rating$3.91$7.00Buy$0.0000.00% ROIJBIOJade Biosciences6/16/2025Upgrade$6.76$14.00Buy$00.0000.00% ROISVRASavara5/28/2025Reiterated Rating$2.04$8.00Buy$0.0000.00% ROIAMGNAmgen5/20/2025Initiated Coverage$276.16$288.00Neutral$000.0000.00% ROIANIPANI Pharmaceuticals5/12/2025Reiterated Rating$63.63$86.00Buy$00.0000.00% ROIVALNValneva5/8/2025Lower Price Target$6.28$14.00Buy$0.0000.00% ROIABBVAbbVie4/29/2025Boost Price Target$192.43$216.00Buy$000.0000.00% ROIUNCYUnicycive Therapeutics4/21/2025Initiated Coverage$6.00$60.00Buy$0.0000.00% ROIABBVAbbVie4/17/2025Reiterated Rating$173.24$214.00Buy$000.0000.00% ROIMRKMerck & Co., Inc.4/17/2025Reiterated Rating$78.09$115.00Buy$000.0000.00% ROITVTXTravere Therapeutics4/14/2025Reiterated Rating$14.76$47.00Buy$00.0000.00% ROIANIPANI Pharmaceuticals4/11/2025Reiterated Rating$65.86$86.00Buy$00.0000.00% ROIJNJJohnson & Johnson4/2/2025Reiterated Rating$155.02Neutral$000.0000.00% ROIASMBAssembly Biosciences3/25/2025Initiated Coverage$11.12$31.00Buy$00.0000.00% ROIPFEPfizer3/18/2025Reiterated Rating$26.27Buy$00.0000.00% ROIPFEPfizer3/12/2025Reiterated Rating$25.67Buy$00.0000.00% ROIJNJJohnson & Johnson3/10/2025Reiterated Rating$168.77Neutral$000.0000.00% ROIANIPANI Pharmaceuticals3/5/2025Boost Price Target$59.23$86.00Buy$00.0000.00% ROIVERAVera Therapeutics2/27/2025Boost Price Target$29.14$61.00Buy$00.0000.00% ROIINSMInsmed2/25/2025Reiterated Rating$78.46$101.00Buy$000.0000.00% ROIMRKMerck & Co., Inc.2/12/2025Lower Price Target$86.53$115.00Buy$000.0000.00% ROIPFEPfizer2/10/2025Reiterated Rating$25.76$33.00Buy$00.0000.00% ROIINSMInsmed2/7/2025Boost Price Target$79.71$101.00Buy$000.0000.00% ROIABBVAbbVie2/3/2025Boost Price Target$183.90$214.00Buy$000.0000.00% ROIJNJJohnson & Johnson2/3/2025Boost Price Target$152.09$166.00Neutral$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageEvercoreRoth MkmWall Street ZenThe Goldman Sachs GroupMizuhoDesjardinsCanadian Imperial Bank of CommerceCitigroupMorgan StanleyRoyal Bank Of CanadaDeutsche Bank AktiengesellschaftBMO Capital MarketsCanaccord Genuity GroupBerenberg BankBNP Paribas Exane Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
